NEXT GENERATION AAV PRODUCTION
By Cytiva
Gene therapy is the most effective and often only treatment option for many severe and life-threatening diseases. Consequently, production processes delivering high yields in scalable formats are needed.
This paper examines how the scalable, stable AAV production platform ELEVECTA brings viral vector manufacturing to the next level and opens a new chapter for the industry, unlocking the full potential of gene therapies.